The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders.

BACKGROUND Metoclopramide hydrochloride, a neuroleptic dopamine receptor antagonist used to treat gastric ailments, is reported to cause extrapyramidal movement disorders. The goals of this study were (1) to determine the prevalence and severity of tardive dyskinesia and acute extrapyramidal movement syndromes including akathisia, acute dystonia, and drug-induced parkinsonism in metoclopramide-treated patients and (2) to compare the prevalence and severity of tardive dyskinesia in metoclopramide-treated diabetics and nondiabetics. METHODS From a list of metoclopramide-treated patients received from the Portland (Ore) Veterans Affairs Medical Center pharmacy, 53 patients met inclusion criteria and 51 (96%) agreed to participate. Controls consisted of a convenience sample drawn from the Portland Veterans Affairs Medical Center Outpatient Clinic who were matched to subjects on age (+/- 10 years), gender, and presence or absence of diabetes. Of 61 potential controls contacted, 51 (84%) agreed to participate. Metoclopramide-treated subjects and controls were seen by a rater who was "blind" to all diagnoses and treatments. The rater performed a standardized examination used to elicit signs and symptoms of tardive dyskinesia and acute extrapyramidal movement syndromes. RESULTS The relative risk for tardive dyskinesia was 1.67 (95% confidence interval, 0.93 to 2.97), and the relative risk for drug-induced parkinsonism was 4.0 (95% confidence interval, 1.5 to 10.5). Metoclopramide-treated patients had significantly greater severity of tardive dyskinesia, drug-induced parkinsonism, and subjective akathisia than controls. Use of metoclopramide was associated with impairment in ambulation and increased use of benzodiazepines. Metoclopramide-treated diabetics had significantly greater severity of tardive dyskinesia than metoclopramide-treated nondiabetics. CONCLUSIONS Metoclopramide use is associated with a significantly increased prevalence and severity of several extrapyramidal movement disorders.

[1]  Jacob Cohen,et al.  Applied multiple regression/correlation analysis for the behavioral sciences , 1979 .

[2]  R. Baldessarini,et al.  Changes in prevalence, severity, and recovery in tardive dyskinesia with age. , 1980, Archives of general psychiatry.

[3]  R. McCallum,et al.  Metoclopramide: pharmacology and clinical application. , 1983, Annals of internal medicine.

[4]  J. Kane,et al.  Research diagnoses for tardive dyskinesia. , 1982, Archives of general psychiatry.

[5]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.

[6]  R. Boys,et al.  Extrapyramidal reactions to metoclopramide and prochlorperazine. , 1989, The Quarterly journal of medicine.

[7]  E. D. Barnhart.  Physicians Desk Reference , 1990 .

[8]  M. Kramer,et al.  Clinical Epidemiology and Biostatistics , 1988, Springer Berlin Heidelberg.

[9]  A. McCall.  Cerebral Microvascular Transport and Metabolism: Implications for Diabetes , 1992 .

[10]  G. Keepers,et al.  Acute Extrapyramidal Syndromes in Neuroleptic-Treated Elders: A Pilot Study , 1991, Journal of geriatric psychiatry and neurology.

[11]  R. Tallis,et al.  Metoclopramide and tardive dyskinesia in the elderly. , 1984, British medical journal.

[12]  J. Grimes,et al.  Adverse neurologic effects of metoclopramide. , 1982, Canadian Medical Association journal.

[13]  J. Waddington.  Schizophrenia, affective psychoses, and other disorders treated with neuroleptic drugs: the enigma of tardive dyskinesia, its neurobiological determinants, and the conflict of paradigms. , 1989, International review of neurobiology.

[14]  D. Greenberg.  Tardive Dyskinesia: A Task Force Report of the American Psychiatric Association , 1993 .

[15]  P. Weiden,et al.  Clinical nonrecognition of neuroleptic-induced movement disorders: a cautionary study. , 1987, American Journal of Psychiatry.

[16]  R. N. Brogden,et al.  Metoclopramide. An updated review of its pharmacological properties and clinical use. , 1983, Drugs.

[17]  L. Ganzini,et al.  The prevalence of tardive dyskinesia in neuroleptic-treated diabetics. A controlled study. , 1991, Archives of general psychiatry.

[18]  A. McCall.  The Impact of Diabetes on the CNS , 1992, Diabetes.

[19]  G. Alexopoulos,et al.  Drug-induced dystonia in young and elderly patients. , 1988, The American journal of psychiatry.

[20]  J. Fleiss.  Statistical methods for rates and proportions , 1974 .

[21]  Dallas W. Anderson,et al.  Prevalence of Parkinson's disease in the biracial population of Copiah County, Mississippi , 1985, Neurology.

[22]  M. Rawlins,et al.  Extrapyramidal reactions with metoclopramide. , 1985, British medical journal.

[23]  B. Wiholm,et al.  Tardive dyskinesia associated with metoclopramide. , 1984, British medical journal.

[24]  D. Casey.  Metoclopramide side effects. , 1983, Annals of internal medicine.

[25]  J. Jankovic,et al.  Metoclopramide-induced movement disorders. Clinical findings with a review of the literature. , 1989, Archives of internal medicine.